Adalimumab biosimilar (Genor Biopharma)
重组抗肿瘤坏死因子-α全人源单抗（嘉和生物）
Report date: 2022/08/12 20:00:41
Base Information
Drug NameAdalimumab biosimilar (Genor Biopharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesBiocndGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A